In a major development a single disposable device and therapy could become the first FDA-approved cellular therapy treatment for osteoarthritis of the knee. The SVF-2 uniquely harvests, isolates, concentrates and extracts the right amount and type of a patient’s own healing cells for a cellular implant to help control pain, reduce inflammation and repair inflamed tissue in the knee. FDA compliant clinical trials for this no-joint-surgery, minimally invasive option have shown no serious adverse events and significant improvements in pain, stiffness and function.